Literature DB >> 18475586

Platelet activating factor synthesis and metabolism in intestinal ischaemia-reperfusion injury.

M J Mangino1, M Murphy, A Bohrer, J Turk.   

Abstract

The object of this study was to characterize the synthesis and metabolism of platelet activating factor (PAF) by intestinal mucosa subjected to ischaemia-reperfusion injury. Canine intestinal mucosa produced 16:0-PAF, 18:0-PAF, and high levels of the corresponding lyso- PAF metabolites. Three h of intestinal ischaemia and ischaemia followed by 1 h of reperfusion did not affect the synthesis or metabolism of PAF by intestinal mucosa. Intestinal mucosa elaborated a factor that rapidly hydrolyzes PAF to lyso-PAF. The observed hydrolysis rate was not altered by ischaemia or ischaemia and reperfusion. In conclusion, this study suggests that intestinal mucosa produces PAF and rapidly hydrolyzes PAF. The PAF synthesis and metabolism rates of intestinal mucosa is not altered by ischaemia reperfusion in this model under the imposed conditions.

Entities:  

Year:  1994        PMID: 18475586      PMCID: PMC2365579          DOI: 10.1155/S0962935194000554

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  27 in total

1.  Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin.

Authors:  B Hendey; C B Klee; F R Maxfield
Journal:  Science       Date:  1992-10-09       Impact factor: 47.728

2.  Probing immunosuppressant action with a nonnatural immunophilin ligand.

Authors:  B E Bierer; P K Somers; T J Wandless; S J Burakoff; S L Schreiber
Journal:  Science       Date:  1990-10-26       Impact factor: 47.728

3.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.

Authors:  S D Wright; R A Ramos; P S Tobias; R J Ulevitch; J C Mathison
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

4.  Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS.

Authors:  J C Mathison; P S Tobias; E Wolfson; R J Ulevitch
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

5.  Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis.

Authors:  A Hirao; Y Kawano; Y Takaue
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

Review 6.  Lipopolysaccharide antagonists.

Authors:  W A Lynn; D T Golenbock
Journal:  Immunol Today       Date:  1992-07

7.  Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.

Authors:  R J Arceci; K Stieglitz; B E Bierer
Journal:  Blood       Date:  1992-09-15       Impact factor: 22.113

8.  Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA.

Authors:  J Friedman; I Weissman
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

9.  Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity.

Authors:  J Liu; M W Albers; T J Wandless; S Luan; D G Alberg; P J Belshaw; P Cohen; C MacKintosh; C B Klee; S L Schreiber
Journal:  Biochemistry       Date:  1992-04-28       Impact factor: 3.162

10.  Differential expression of cytokines in human blood monocyte subpopulations.

Authors:  H W Ziegler-Heitbrock; M Ströbel; D Kieper; G Fingerle; T Schlunck; I Petersmann; J Ellwart; M Blumenstein; J G Haas
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.